| The pancreas cancer microenvironment C Feig, A Gopinathan, A Neesse, DS Chan, N Cook, DA Tuveson Clinical cancer research 18 (16), 4266-4276, 2012 | 1405 | 2012 |
| Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer MA Jacobetz, DS Chan, A Neesse, TE Bapiro, N Cook, KK Frese, C Feig, ... Gut, gutjnl-2012-302529, 2012 | 1138 | 2012 |
| Stromal biology and therapy in pancreatic cancer A Neesse, P Michl, KK Frese, C Feig, N Cook, MA Jacobetz, MP Lolkema, ... Gut 60 (6), 861-868, 2011 | 902 | 2011 |
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial HER Ford, A Marshall, JA Bridgewater, T Janowitz, FY Coxon, J Wadsley, ... The Lancet Oncology 15 (1), 78-86, 2014 | 680 | 2014 |
| nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer KK Frese, A Neesse, N Cook, TE Bapiro, MP Lolkema, DI Jodrell, ... Cancer discovery 2 (3), 260-269, 2012 | 467 | 2012 |
| Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice E Maniati, M Bossard, N Cook, JB Candido, N Emami-Shahri, ... The Journal of clinical investigation 121 (12), 4685, 2011 | 270 | 2011 |
| Small cell carcinoma of the urinary bladder: a 15‐year retrospective review of treatment and survival in the Anglian Cancer Network M Mukesh, N Cook, AE Hollingdale, NL Ainsworth, SG Russell BJU international 103 (6), 747-752, 2009 | 137 | 2009 |
| Early phase clinical trials to identify optimal dosing and safety N Cook, AR Hansen, LL Siu, AR Abdul Razak Molecular oncology 9 (5), 997-1007, 2015 | 121 | 2015 |
| Predictive in vivo animal models and translation to clinical trials N Cook, DI Jodrell, DA Tuveson Drug discovery today 17 (5), 253-260, 2012 | 119 | 2012 |
| A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC). N Cook, B Basu, DM Smith, A Gopinathan, TJ Evans, WP Steward, ... Journal of Clinical Oncology 32 (15_suppl), 4116-4116, 2014 | 114* | 2014 |
| Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma N Cook, KK Frese, TE Bapiro, MA Jacobetz, A Gopinathan, JL Miller, ... Journal of Experimental Medicine, jem. 20111923, 2012 | 114 | 2012 |
| Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice A Gopinathan, GM DeNicola, KK Frese, N Cook, FA Karreth, J Mayerle, ... Gut, gutjnl-2011-300850, 2011 | 86 | 2011 |
| Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data A Marshall, C Connell, H Ford, J Dunn, JH Kang, N Cook, ... British journal of cancer 114 (4), 381, 2016 | 66 | 2016 |
| A novel method for quantification of gemcitabine and its metabolites 2′, 2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with … TE Bapiro, FM Richards, MA Goldgraben, KP Olive, B Madhu, KK Frese, ... Cancer chemotherapy and pharmacology 68 (5), 1243-1253, 2011 | 64 | 2011 |
| Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials RJ Brais, SE Davies, M O’Donovan, BW Simpson, N Cook, WC Darbonne, ... Pancreatology 12 (1), 8-15, 2012 | 57 | 2012 |
| FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience MK Chllamma, N Cook, NC Dhani, K Giby, A Dodd, L Wang, DW Hedley, ... British journal of cancer 115 (6), 649-654, 2016 | 47 | 2016 |
| Exome-wide association study of pancreatic cancer risk RC Grant, RE Denroche, A Borgida, C Virtanen, N Cook, AL Smith, ... Gastroenterology, 2017 | 44 | 2017 |
| Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer A Courtin, FM Richards, TE Bapiro, JL Bramhall, A Neesse, N Cook, ... PloS one 8 (6), e67330, 2013 | 37 | 2013 |
| K‐Ras‐Driven Pancreatic Cancer Mouse Model for Anticancer Inhibitor Analyses N Cook, KP Olive, K Frese, DA Tuveson Methods in enzymology 439, 73-85, 2008 | 36 | 2008 |
| A phase 2 study of vatalanib in metastatic melanoma patients N Cook, B Basu, S Biswas, P Kareclas, C Mann, C Palmer, A Thomas, ... European Journal of Cancer 46 (15), 2671-2673, 2010 | 30 | 2010 |
